Afleveringen
-
Guest: Lori J. Wirth, MD
Head and neck cancers are the seventh most common cancers globally and are increasing in prevalence.1,2 To dive further into the intricacies of this early-stage cancer, join Dr. Lori Wirth, Medical Oncologist in the Head and Neck Oncology Program at Massachusetts General Hospital in Boston.
References:
Gormley M, et al. Br Dent J. 2022;233(9):780-786. Barsouk A, et al. Med Sci (Basel). 2023;11(2):42.
©2024 Merck KGaA, Darmstadt, Germany or its affiliates. All rights reserved.
EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada.
US-NONO-00581 05/2024 -
Host: Jennifer Caudle, DO
Guest: Joyce O'Shaughnessy, MD
The results from the phase III EMERALD trial led to the approval of ORSERDU® (elacestrant) as the first oral selective estrogen receptor degrader for ER-positive/HER2-negative metastatic breast cancer patients with ESR1 mutations after disease progression following at least one line of endocrine therapy.1 But given the results from prior analyses, clinicians wanted to better understand the data for elacestrant in subgroups of patients with key clinical or biomarker characteristics, and so a post hoc analysis of elacestrant in these subgroups who typically have a poorer prognosis was conducted. Explore the EMERALD trial and the key outcomes from this subgroup analysis with Dr. Jennifer Caudle and medical oncologist Dr. Joyce O'Shaughnessy.
-
Zijn er afleveringen die ontbreken?
-
Host: Jennifer Caudle, DO
Guest: Tamera A. Paczos, MD, FACOG, FACP
The utility of p16 and Ki-67 immunostaining in biopsies has helped lead to the development of dual staining in cytology specimens. So what do clinicians need to know about the dual stain cytology test? Take a deep dive into this topic as Dr. Jennifer Caudle is joined by Dr. Tamera A. Paczos, Vice President, Associate Chief Medical Officer with BioReference Laboratories.
COBAS and CINTEC are trademarks of Roche.
All other product names and trademarks are the property of their respective owners. 02/23 -
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: William F.C. Rigby, MD
Polymyalgia rheumatica (PMR) is an inflammatory rheumatic condition that can be difficult to diagnose and treat. For instance, PMR is a diagnosis of exclusion, and it can mimic a wide variety of other conditions. And once a patient is accurately diagnosed, the standard-of-care treatment with glucocorticoids may result in toxicity for some patients. Learn more about these and other diagnostic and treatment challenges as well as other treatment options with Dr. Charles Turck and Dr. William Rigby, Professor of Medicine and of Microbiology and Immunology at the Geisel School of Medicine at Dartmouth.
© 2024 Sanofi and Regeneron Pharmaceuticals, Inc.
All rights reserved.
MAT-US-2403256 v1.0 - P
Expiration Date 04/16/2025 -
Guest: Adam Narloch
Guest: Michelle Hermiston, MD, PhD
Adam Narloch speaks with Dr Michelle Hermiston to discuss the history of hemophagocytic lymphohistiocytosis (HLH) and advances in understanding this rare disease. Dr Hermiston is a pediatric hematologist-oncologist, a bone marrow transplant specialist, and the Director of the Pediatric Immunotherapy Program at UCSF Benioff Children’s Hospital. Join us as we start our journey into the world of HLH!
© 2024 Sobi, Inc. All Rights Reserved. NP-34329 04/24
-
Host: Richard Lafayette, MD, FACP
Expert Nephrologist Richard Lafayette, MD, FACP, gives an overview of top abstracts from Kidney Week 2023 and updates on emerging therapies for IgAN.
-
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: John Stone, MD, MPH
Glucocorticoids are often successfully used as the mainstay of treatment for many inflammatory conditions, but adverse events associated with glucocorticoids use are common. Fortunately, there are steps we can take to reduce the risk of glucocorticoid toxicity, like monitoring patients, educating them on the possible side effects, and considering alternative treatments where available. Tune in to learn more about the side effects, risk factors, and prevention strategies with Dr. Charles Turck and Dr. John Stone.
© 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All rights reserved.
MAT-US-2310647 v1.0 - P
Expiration Date 04/16/2025 -
Guest: Dena Goffman, MD
Dr. Dena Goffman believes that better maternal care requires a proactive, system-wide approach and is making her vision a reality at NewYork-Presbyterian. She focuses on implementing guidelines that standardize care across all of NewYork-Presbyterian’s hospitals. Dr. Goffman has also aided in FDA approval and adoption of a new, ingenious hemorrhage tool and embraced simulations to train and improve the skills of healthcare professionals throughout the labor and delivery process. Join health and science journalist Catherine Price as she speaks with Dr. Dena Goffman, Vice Chair for Quality and Patient Safety and the Associate Chief and Quality Officer for Obstetrics for NewYork-Presbyterian, about how her work has helped establish goals and quality standards for safer labor and delivery.
© 2024 NewYork-Presbyterian
-
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Arnaud Bourdin, MD, PhD
Since many severe asthma patients have been shown to have mucus plugs, it’s important to understand the role they plan in severe asthma. Join us as we discuss an exploratory study and the role of mucus plugging in severe asthma with Dr. Charles Turck and Professor Arnaud Bourdin. Professor Bourdin is the Head of Pulmonology at the Arnaud de Villeneuve Hospital in Montpellier, France.
TEZSPIRE is a registered trademark of Amgen Inc. and AstraZeneca.
©2024 Amgen and AstraZeneca. All rights reserved. US-83499 Last Updated 1/24 -
Guest: Pierre Elias, MD
In this episode, you’ll gain insights into Dr. Elias’ innovative approach, integrating technology, data science, and medicine to develop algorithms that aim to enhance accuracy in predicting cardiovascular disease while allowing them to focus on providing personalized care to their patients. This could even help diagnose patients before symptoms occur. Join health and science journalist Catherine Price as she speaks with Dr. Pierre Elias, Medical Director of Artificial Intelligence at NewYork-Presbyterian, about the future of technology in medicine.
© 2024 NewYork-Presbyterian
-
Guest: Michael Kaplitt, MD, PhD
For the first time, Dr. Michael Kaplitt was able to perform a trial for a neurological gene therapy that was administered in a human patient to address damaged brain cells caused by Parkinson’s disease. This procedure used an adeno-associated virus to deliver a gene into the brain of a patient with Parkinson’s. The results were groundbreaking and paved new avenues for research in neurological gene therapy, such as preventative intervention. Join health and science journalist Catherine Price as she speaks with Dr. Michael Kaplitt, Executive Vice Chair of the Department of Neurological Surgery at NewYork-Presbyterian/Weill Cornell Medicine, as he discusses the story of his breakthrough and how he’s continuing to evolve the field of neurosurgery.
© 2024 NewYork-Presbyterian
-
Guest: Conor Liston, MD, PhD
For patients diagnosed with depression for the first time the recommended course of treatment is the same; however, there’s a large patient population for whom these treatments won’t work. So it became increasingly important for Dr. Liston to map the brains of people suffering from major depression to see how it was impacting brain structures and symptoms. The research showed that certain networks expanded in the brains of patients who had depression and pushed into other networks. Learn more about identifying how these symptoms impact the patient’s brains, analyzing the best course for treatments, and how this research could be the key to effectively using transcranial magnetic stimulation to help patients with treatment-resistant depression. Join health and science journalist Catherine Price as she speaks with Dr. Conor Michael Liston, Psychiatrist at NewYork-Presbyterian/Weill Cornell Medicine, to discuss these approaches to help treatment-resistant depression.
© 2024 NewYork-Presbyterian
-
Guest: Christopher Petit, MD
Pulmonary vein stenosis (PVS) is a rare and challenging heart condition, which narrows blood vessels around the lungs and typically impacts newborn children. Historically, the rates of survival have been low, but with Dr. Petit leading the development of innovative techniques and treatments, the trajectory of patients’ lives could positively change. Join health and science journalist Catherine Price and Dr. Christopher Petit, Co-Director of Children’s Heart Center at NewYork-Presbyterian Morgan Stanely Children’s Hospital and Division Chief of Pediatric Cardiology at Columbia University, to discuss breakthroughs and treatments that are making a big impact on pediatric survival rates.
© 2024 NewYork-Presbyterian
-
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jamie Koprivnikar, MD
Patients with lower-risk myelodysplastic syndromes (MDS) lack treatment options, specifically in treating anemia. However, the FDA approval of Reblozyl (luspatercept-aamt) as a first-line therapy for treating anemia in ESA-naïve patients with lower-risk MDS presents an option for this patient population. Tune in to learn more about evaluating patients with MDS, the potential of Reblozyl, and where it fits into the treatment landscape with Dr. Charles Turck as he takes a deep dive with Dr. Jamie Koprivnikar, MD, Hematologist, Oncologist, at Hackensack Meridian Health.
REBLOZYL® is a trademark of Celgene Corporation, a Bristol Myers Squibb company.
REBLOZYL® is licensed from Merck & Co. Inc., Rahway, NJ, USA and its affiliates.
© 2024 Bristol-Myers Squibb Company
2007-US-2300376 03/24 -
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Arnaud Bourdin, MD, PhD
It’s only been a recent discovery that mucus plugging may be present and persistent in chronic severe asthma.1 In fact, studies have shown that mucus plugs may drive some lung function deficits in severe asthma.1 Given this recent finding, Dr Charles Turck speaks with Professor Arnaud Bourdin about the clinical significance and pathogenesis of mucus plugging in severe asthma. Professor Bourdin is Head of Pulmonology at Arnaud de Villeneuve Hospital in Montpellier, France.
Reference:
Dunican EM, Watchorn DC, Fahy JV. Ann Am Thorac Soc. 2018;15(Suppl 3):S184-S191. doi:10.1513/AnnalsATS.201807-485AW©2024 Amgen and AstraZeneca. All rights reserved. US-86740 Last Updated 3/24
-
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Brian Iacoviello, MD
Since the thinking part of depression may involve getting stuck on the sad or the negative thoughts, there is a need to focus on not just cognitive control for information but for emotional information processing.1 And that fits with the picture that we get from brain imaging research that shows hyperactivity in the emotion-processing region of the brain and a quieting-down of the cognitive control region of the brain when people are depressed.1 To take a deep dive, join Dr. Brian Iacoviello, Assistant Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai in New York City.
Reference
Iacoviello BM, Wu G, Alvarez E, et al. Cognitive-emotional training as an intervention for major depressive disorder. Depress Anxiety. 2014;31(8):699-706.January 2024 US.UNB.X.23.00076
-
Guest: Aderonke Pederson, MD
Major depressive disorder is a mental health condition that affects millions of Americans,1 and for the past several decades, treatment has consisted mainly of antidepressant therapy and psychotherapy.2,3 However, many patients still don't achieve their treatment goals and there are many potential barriers to accessing treatment. Learn more about these unmet needs in major depressive disorder care that underscore the importance of finding new treatment approaches with Dr. Aderonke Pederson, Assistant Professor of Psychiatry at Harvard Medical School.
References:
National Institute of Mental Health. Major depression. National Institute of Mental Health. July 2023. Accessed November 10, 2023. https://www.nimh.nih.gov/health/statistics/major-depression National Institute of Mental Health. Depression. National Institute of Mental Health. September 2023. Accessed November 10, 2023. https://www.nimh.nih.gov/health/topics/depression American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder, 3rd ed. American Psychiatric Association Publishing. 2010. Accessed November 10, 2023. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdfJanuary 2024 US.UNB.X.23.00150
-
Host: Jennifer Caudle, DO
Guest: Manpreet Mundi, MD
Enteral nutrition intolerance is quite prevalent as it can be seen in up to 40 percent of patients who are tube fed. Due to the significant consequences of intolerance, there’s an urgency to manage patients symptoms, and one option that’s been shown to help is peptide-based tube feeding formulas. Joining Dr. Jennifer Caudle to talk about the management of enteral feeding intolerance with peptide-based tube feeding formulas is Dr. Manpreet Mundi, Professor of Medicine in the Department of Endocrinology at the Mayo Clinic College of Medicine and Science in Rochester, Minnesota.
All trademarks are owned by Société des Produits Nestlé S.A., Vevey, Switzerland. ©2023 Nestlé
-
Guest: Mark Haas, MD
Kidney biopsy is the gold standard for the diagnosis of immunoglobin A (IgA) nephropathy and complement 3 glomerulopathy (C3G),1,2 and the accurate interpretation of kidney biopsy findings is important not only for diagnosis but also guiding clinical management of these conditions. Learn more about what the diagnostic process and findings for IgA nephropathy and C3G look like with Dr Mark Haas, a renal pathologist at Cedars-Sinai Medical Center in Los Angeles.
References:
Mehdi A, Taliercio JJ. Cleve Clin J Med. 2023;90(6)(suppl 1):e1-e4. doi:10.3949/ccjm.90.e-s1.02 Caravaca-Fontán F, Lucientes L, Cavero T, Praga M. Nephron. 2020;144(6):272-280. doi:10.1159/000507254319698 12/23
-
Guest: Jai Radhakrishnan, MD
The most widely accepted mechanism for the pathogenesis of immunoglobin A (IgA) nephropathy is referred to as the “four-hit model,” which is a sequence of four events that can occur.1-3 Here to break down each of those four stages is Dr. Jai Radhakrishnan, a nephrologist at Columbia University Medical Center in New York.
References:
Knoppova B, Reily C, King RG, et al. J Clin Med. 2021;10(19):4501. doi:10.3390/jcm10194501 Maillard N, Wyatt RJ, Julian BA, et al. J Am Soc Nephrol. 2015;26(7):1503-1512. doi:10.1681/ASN.2014101000 Chang S, Li X-K. Front Med (Lausanne). 2020;7:92. doi:10.3389/fmed.2020.00092319698 12/23
- Laat meer zien